Search

Your search keyword '"Chua, Kian-Ngiap"' showing total 21 results
Start Over Author "Chua, Kian-Ngiap"
21 results on '"Chua, Kian-Ngiap"'

1. Supplementary Figure S4 from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

2. Supplementary Text from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

3. Data from MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, primary, Sim, Wen Jing, primary, Ng, Hsien Chun, primary, Bi, Chonglei, primary, Ho, Jingshan, primary, Nga, Min En, primary, Pang, Yin Huei, primary, Ong, Weijie Richard, primary, Soo, Ross Andrew, primary, Huynh, Hung, primary, Chng, Wee Joo, primary, Thiery, Jean-Paul, primary, and Goh, Boon Cher, primary

Published
2023
Full Text
View/download PDF

14. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma

Author

Kong, Li Ren, primary, Chua, Kian Ngiap, additional, Sim, Wen Jing, additional, Ng, Hsien Chun, additional, Bi, Chonglei, additional, Ho, Jingshan, additional, Nga, Min En, additional, Pang, Yin Huei, additional, Ong, Weijie Richard, additional, Soo, Ross Andrew, additional, Huynh, Hung, additional, Chng, Wee Joo, additional, Thiery, Jean-Paul, additional, and Goh, Boon Cher, additional

Published
2015
Full Text
View/download PDF

15. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment

Author

Massachusetts Institute of Technology. Department of Biological Engineering, Massachusetts Institute of Technology. Department of Mechanical Engineering, Kamm, Roger Dale, Zervantonakis, Ioannis K., Aref, Amir R., Huang, Ruby Yun-Ju, Yu, Weimiao, Chua, Kian-Ngiap, Sun, Wei, Tu, Ting-Yuan, Bai, Jing, Sim, Wen-Jing, Thiery, Jean Paul, Massachusetts Institute of Technology. Department of Biological Engineering, Massachusetts Institute of Technology. Department of Mechanical Engineering, Kamm, Roger Dale, Zervantonakis, Ioannis K., Aref, Amir R., Huang, Ruby Yun-Ju, Yu, Weimiao, Chua, Kian-Ngiap, Sun, Wei, Tu, Ting-Yuan, Bai, Jing, Sim, Wen-Jing, and Thiery, Jean Paul

Abstract

Epithelial–mesenchymal transition (EMT) plays a critical role in the early stages of dissemination of carcinoma leading to metastatic tumors, which are responsible for over 90% of all cancer-related deaths. Current therapeutic regimens, however, have been ineffective in the cure of metastatic cancer, thus an urgent need exists to revisit existing protocols and to improve the efficacy of newly developed therapeutics. Strategies based on preventing EMT could potentially contribute to improving the outcome of advanced stage cancers. To achieve this goal new assays are needed to identify targeted drugs capable of interfering with EMT or to revert the mesenchymal-like phenotype of carcinoma to an epithelial-like state. Current assays are limited to examining the dispersion of carcinoma cells in isolation in conventional 2-dimensional (2D) microwell systems, an approach that fails to account for the 3-dimensional (3D) environment of the tumor or the essential interactions that occur with other nearby cell types in the tumor microenvironment. Here we present a microfluidic system that integrates tumor cell spheroids in a 3D hydrogel scaffold, in close co-culture with an endothelial monolayer. Drug candidates inhibiting receptor activation or signal transduction pathways implicated in EMT have been tested using dispersion of A549 lung adenocarcinoma cell spheroids as a metric of effectiveness. We demonstrate significant differences in response to drugs between 2D and 3D, and between monoculture and co-culture., Singapore. National Research Foundation (Singapore MIT Alliance for Research and Technology's BioSystems and Micromechanics Inter-Disciplinary Research programme), National University of Singapore (Cancer Science Institute), Singapore. Agency for Science, Technology and Research, Singapore. Institute of Molecular and Cell Biology (IMCB core funding A*STAR)

Published
2014

18. Quantification of L‐ergothioneine in human plasma and erythrocytes by liquid chromatography‐tandem mass spectrometry

Author

Wang, Ling‐Zhi, primary, Thuya, Win‐Lwin, additional, Toh, Dorothy Su‐Lin, additional, Lie, Michael George‐Limenta, additional, Lau, Jie‐Ying Amelia, additional, Kong, Li‐Ren, additional, Wan, Seow‐Ching, additional, Chua, Kian‐Ngiap, additional, Lee, Edmund Jon‐Deoon, additional, and Goh, Boon‐Cher, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results